|
1
|
The therapeutic role of 5-HT1A and 5-HT2A receptors in depression.
|
J Psychiatry Neurosci
|
2004
|
1.61
|
|
2
|
Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
|
J Clin Psychiatry
|
2010
|
1.55
|
|
3
|
Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex.
|
Cereb Cortex
|
2004
|
1.48
|
|
4
|
Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.
|
Cereb Cortex
|
2004
|
1.43
|
|
5
|
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.
|
Int J Neuropsychopharmacol
|
2011
|
1.32
|
|
6
|
The somatodendritic release of dopamine in the ventral tegmental area and its regulation by afferent transmitter systems.
|
Neurosci Biobehav Rev
|
2004
|
1.32
|
|
7
|
Origin and functional role of the extracellular serotonin in the midbrain raphe nuclei.
|
Brain Res Brain Res Rev
|
2002
|
1.30
|
|
8
|
Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex.
|
Cereb Cortex
|
2008
|
1.26
|
|
9
|
Antipsychotic drugs reverse the disruption in prefrontal cortex function produced by NMDA receptor blockade with phencyclidine.
|
Proc Natl Acad Sci U S A
|
2007
|
1.23
|
|
10
|
Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat.
|
Neuropsychopharmacology
|
2007
|
1.19
|
|
11
|
Serotonin modulation of cortical neurons and networks.
|
Front Integr Neurosci
|
2013
|
1.15
|
|
12
|
In vivo modulation of the activity of pyramidal neurons in the rat medial prefrontal cortex by 5-HT2A receptors: relationship to thalamocortical afferents.
|
Cereb Cortex
|
2003
|
1.12
|
|
13
|
In vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors.
|
Cereb Cortex
|
2004
|
1.11
|
|
14
|
Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action.
|
J Neurosci
|
2005
|
1.10
|
|
15
|
Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.
|
CNS Drugs
|
2013
|
1.10
|
|
16
|
Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA.
|
Cereb Cortex
|
2004
|
1.09
|
|
17
|
Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
|
J Neurochem
|
2005
|
1.09
|
|
18
|
The selective 5-HT2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine.
|
Neuropsychopharmacology
|
2005
|
1.06
|
|
19
|
Activation of thalamocortical networks by the N-methyl-D-aspartate receptor antagonist phencyclidine: reversal by clozapine.
|
Biol Psychiatry
|
2011
|
1.05
|
|
20
|
The hallucinogen DOI reduces low-frequency oscillations in rat prefrontal cortex: reversal by antipsychotic drugs.
|
Biol Psychiatry
|
2008
|
1.05
|
|
21
|
Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.
|
EMBO J
|
2007
|
1.04
|
|
22
|
Strategies for producing faster acting antidepressants.
|
Drug Discov Today
|
2005
|
1.02
|
|
23
|
Acute 5-HT₁A autoreceptor knockdown increases antidepressant responses and serotonin release in stressful conditions.
|
Psychopharmacology (Berl)
|
2012
|
1.01
|
|
24
|
The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity.
|
J Neurochem
|
2005
|
0.98
|
|
25
|
Pyramidal neurons in rat prefrontal cortex projecting to ventral tegmental area and dorsal raphe nucleus express 5-HT2A receptors.
|
Cereb Cortex
|
2008
|
0.98
|
|
26
|
Regulation of cAMP phosphodiesterase mRNAs expression in rat brain by acute and chronic fluoxetine treatment. An in situ hybridization study.
|
Neuropharmacology
|
2002
|
0.95
|
|
27
|
5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons.
|
Cereb Cortex
|
2011
|
0.92
|
|
28
|
Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
|
Int J Neuropsychopharmacol
|
2010
|
0.90
|
|
29
|
5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study.
|
Psychopharmacology (Berl)
|
2003
|
0.88
|
|
30
|
Control of the serotonergic system by the medial prefrontal cortex: potential role in the etiology of PTSD and depressive disorders.
|
Neurotox Res
|
2003
|
0.87
|
|
31
|
Dopamine neurotransmission and atypical antipsychotics in prefrontal cortex: a critical review.
|
Curr Top Med Chem
|
2012
|
0.86
|
|
32
|
GABAB receptor mRNA in the raphe nuclei: co-expression with serotonin transporter and glutamic acid decarboxylase.
|
J Neurochem
|
2003
|
0.86
|
|
33
|
Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors.
|
Int J Neuropsychopharmacol
|
2010
|
0.85
|
|
34
|
Clozapine Reverses Phencyclidine-Induced Desynchronization of Prefrontal Cortex through a 5-HT(1A) Receptor-Dependent Mechanism.
|
Neuropsychopharmacology
|
2011
|
0.85
|
|
35
|
Role of different monoamine receptors controlling MK-801-induced release of serotonin and glutamate in the medial prefrontal cortex: relevance for antipsychotic action.
|
Int J Neuropsychopharmacol
|
2008
|
0.84
|
|
36
|
In vivo efflux of serotonin in the dorsal raphe nucleus of 5-HT1A receptor knockout mice.
|
J Neurochem
|
2004
|
0.84
|
|
37
|
Clozapine and olanzapine, but not haloperidol, suppress serotonin efflux in the medial prefrontal cortex elicited by phencyclidine and ketamine.
|
Int J Neuropsychopharmacol
|
2005
|
0.84
|
|
38
|
Clozapine does not require 5-HT1A receptors to block the locomotor hyperactivity induced by MK-801 Clz and MK-801 in KO1A mice.
|
Neuropharmacology
|
2010
|
0.83
|
|
39
|
Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.
|
Neuropharmacology
|
2012
|
0.83
|
|
40
|
Catecholamine/Serotonin interactions: systems thinking for brain function and disease.
|
Adv Pharmacol
|
2013
|
0.82
|
|
41
|
Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
|
Curr Pharm Des
|
2010
|
0.82
|
|
42
|
Simultaneous projections from prefrontal cortex to dopaminergic and serotonergic nuclei.
|
Int J Neuropsychopharmacol
|
2010
|
0.82
|
|
43
|
NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.
|
Neurotox Res
|
2008
|
0.81
|
|
44
|
Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist.
|
Eur Neuropsychopharmacol
|
2005
|
0.81
|
|
45
|
An autoradiographic study of the influence of pindolol upon [35S]GTPgammaS binding in rat, guinea pig and human brain.
|
Int J Neuropsychopharmacol
|
2004
|
0.81
|
|
46
|
Importance of inter-hemispheric prefrontal connection in the effects of non-competitive NMDA receptor antagonists.
|
Int J Neuropsychopharmacol
|
2011
|
0.81
|
|
47
|
In vivo modulation of 5-hydroxytryptamine release in mouse prefrontal cortex by local 5-HT(2A) receptors: effect of antipsychotic drugs.
|
Eur J Neurosci
|
2003
|
0.80
|
|
48
|
Association between CCK-AR gene and schizophrenia with auditory hallucinations.
|
Psychiatr Genet
|
2007
|
0.80
|
|
49
|
Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action.
|
Int J Neuropsychopharmacol
|
2013
|
0.80
|
|
50
|
Pindolol augmentation enhances response outcomes in first depressive episodes.
|
Eur Neuropsychopharmacol
|
2009
|
0.79
|
|
51
|
Stimulation of alpha1-adrenoceptors in the rat medial prefrontal cortex increases the local in vivo 5-hydroxytryptamine release: reversal by antipsychotic drugs.
|
J Neurochem
|
2003
|
0.79
|
|
52
|
Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist.
|
Neuropsychopharmacology
|
2002
|
0.79
|
|
53
|
In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat.
|
Psychopharmacology (Berl)
|
2011
|
0.78
|
|
54
|
A functional leptin system is essential for sodium tungstate antiobesity action.
|
Endocrinology
|
2008
|
0.77
|
|
55
|
The absence of 5-HT(1A) receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex.
|
Psychopharmacology (Berl)
|
2008
|
0.77
|
|
56
|
Control of serotonergic neurons in the dorsal raphe nucleus by the lateral hypothalamus.
|
Brain Res
|
2002
|
0.76
|
|
57
|
Effects of acute olanzapine after sustained fluoxetine on extracellular monoamine levels in the rat medial prefrontal cortex.
|
Eur J Pharmacol
|
2005
|
0.76
|
|
58
|
Antipsychotic drugs reverse the AMPA receptor-stimulated release of 5-HT in the medial prefrontal cortex.
|
J Neurochem
|
2007
|
0.76
|
|
59
|
Expression of α(1)-adrenergic receptors in rat prefrontal cortex: cellular co-localization with 5-HT(2A) receptors.
|
Int J Neuropsychopharmacol
|
2012
|
0.76
|
|
60
|
Prefrontal cortex lesions cause only minor effects on the hyperlocomotion induced by MK-801 and its reversal by clozapine.
|
Int J Neuropsychopharmacol
|
2008
|
0.75
|
|
61
|
[Glutamatergic antidepressants? The intriguing antidepressant properties of ketamine].
|
Rev Psiquiatr Salud Ment
|
2011
|
0.75
|
|
62
|
Preclinical models of schizophrenia.
|
Int J Neuropsychopharmacol
|
2013
|
0.75
|